Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 194
2002 175
2003 183
2004 179
2005 284
2006 296
2007 279
2008 293
2009 288
2010 307
2011 366
2012 314
2013 397
2014 431
2015 554
2016 473
2017 446
2018 613
2019 813
2020 1186
2021 1218
2022 1139
2023 1805
2024 797

Text availability

Article attribute

Article type

Publication date

Search Results

11,351 results

Results by year

Filters applied: . Clear all
Page 1
Peptide nanovaccine in melanoma immunotherapy.
Dehghankhold M, Sadat Abolmaali S, Nezafat N, Mohammad Tamaddon A. Dehghankhold M, et al. Int Immunopharmacol. 2024 Mar 10;129:111543. doi: 10.1016/j.intimp.2024.111543. Epub 2024 Jan 31. Int Immunopharmacol. 2024. PMID: 38301413 Review.
Current landscape of long COVID clinical trials.
Bhattacharya M, Chatterjee S, Saxena S, Nandi SS, Lee SS, Chakraborty C. Bhattacharya M, et al. Int Immunopharmacol. 2024 Mar 26;132:111930. doi: 10.1016/j.intimp.2024.111930. Online ahead of print. Int Immunopharmacol. 2024. PMID: 38537538 Review.
Defensins: A novel weapon against Mycobacterium tuberculosis?
Gao X, Feng J, Wei L, Dong P, Chen J, Zhang L, Yang Y, Xu L, Wang H, Luo J, Qin M. Gao X, et al. Int Immunopharmacol. 2024 Jan 25;127:111383. doi: 10.1016/j.intimp.2023.111383. Epub 2023 Dec 20. Int Immunopharmacol. 2024. PMID: 38118315 Review.
SRSF10 facilitates HCC growth and metastasis by suppressing CD8+T cell infiltration and targeting SRSF10 enhances anti-PD-L1 therapy.
Luo X, Zhang Z, Li S, Wang Y, Sun M, Hu D, Jiang J, Wang Y, Ji X, Chen X, Zhang B, Liang H, Li Y, Liu B, Xu X, Wang S, Xu S, Nie Y, Wu K, Fan D, Liu D, Huang W, Xia L. Luo X, et al. Int Immunopharmacol. 2024 Jan 25;127:111376. doi: 10.1016/j.intimp.2023.111376. Epub 2023 Dec 18. Int Immunopharmacol. 2024. PMID: 38113691 Free article.
CD155 as an emerging target in tumor immunotherapy.
Wu JW, Liu Y, Dai XJ, Liu HM, Zheng YC, Liu HM. Wu JW, et al. Int Immunopharmacol. 2024 Apr 20;131:111896. doi: 10.1016/j.intimp.2024.111896. Epub 2024 Mar 22. Int Immunopharmacol. 2024. PMID: 38518596 Review.
11,351 results
You have reached the last available page of results. Please see the User Guide for more information.